Great Point Partners LLC Sells 329,397 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Great Point Partners LLC reduced its position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 17.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,529,338 shares of the company’s stock after selling 329,397 shares during the quarter. Vistagen Therapeutics comprises about 1.0% of Great Point Partners LLC’s portfolio, making the stock its 27th largest position. Great Point Partners LLC owned about 0.06% of Vistagen Therapeutics worth $5,322,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Armistice Capital LLC acquired a new stake in shares of Vistagen Therapeutics during the 4th quarter worth approximately $2,457,000. AdvisorShares Investments LLC acquired a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at $279,000. ADAR1 Capital Management LLC acquired a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at $1,262,000. BVF Inc. IL bought a new position in shares of Vistagen Therapeutics in the 4th quarter valued at $10,280,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Vistagen Therapeutics during the 1st quarter worth $169,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, William Blair raised Vistagen Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th.

Vistagen Therapeutics Price Performance

VTGN stock opened at $3.03 on Tuesday. Vistagen Therapeutics, Inc. has a 1 year low of $2.45 and a 1 year high of $5.86. The stock has a market cap of $81.89 million, a price-to-earnings ratio of -1.46 and a beta of 0.80. The company has a 50 day simple moving average of $3.42 and a 200 day simple moving average of $3.94.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.30 million. Vistagen Therapeutics had a negative return on equity of 35.12% and a negative net margin of 3,421.85%. During the same period in the prior year, the company earned ($0.94) EPS. On average, equities research analysts anticipate that Vistagen Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.